Selecta Biosciences, Inc. Enters Into Exclusive License Agreement With 3SBio Inc. To Develop Drug Candidate To Treat Gout

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced it has entered into an exclusive license with 3SBio for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. Pegsiticase has shown the ability to efficiently reduce plasma uric acid levels in gout patients in successful U.S. Phase 1 clinical tests. The exclusive license enables Selecta to develop pegsiticase in patients with refractory and tophaceous gout and apply its immunomodulatory Synthetic Vaccine Particle (SVP) platform to optimize the safety and efficacy profile for patients at risk of immunogenicity. SEL-212 is a novel product that combines Selecta’s proprietary SVP with 3SBio’s pegsiticase and is designed to be the first non-immunogenic version of uricase.

Help employers find you! Check out all the jobs and post your resume.